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Abstract
 
Immune regulatory CD4
 
 
 
CD25
 
 
 
 cells play a vital role in the induction and maintenance of
self-tolerance and are essential for T cell homeostasis and the prevention of autoimmunity. In-
duction of tolerance to allogeneic donor grafts is a clinically desirable goal in bone marrow and
solid organ transplantation. To determine whether CD4
 
 
 
CD25
 
 
 
 cells regulate T cell responses
to alloantigen and are critical for tolerance induction, murine CD4
 
 
 
 T cells were tolerized to
alloantigen via ex vivo CD40 ligand (CD40L)/CD40 or CD28/cytotoxic T lymphocyte–asso-
ciated antigen 4/B7 blockade resulting in secondary mixed leukocyte reaction hyporesponsive-
ness and tolerance to alloantigen in vivo. CD4
 
 
 
CD25
 
 
 
 T cells were found to be potent regu-
lators of alloresponses. Depletion of CD4
 
 
 
CD25
 
 
 
 T cells from the CD4
 
 
 
 responder
population completely abrogated ex vivo tolerance induction to alloantigen as measured by in-
tact responses to alloantigen restimulation in vitro and in vivo. Addback of CD4
 
 
 
CD25
 
 
 
 T
cells to CD4
 
 
 
CD25
 
  
 
cultures restored tolerance induction. These data are the first to indicate
that CD4
 
 
 
CD25
 
 
 
 cells are essential for the induction of tolerance to alloantigen and have im-
portant implications for tolerance-inducing strategies targeted at T cell costimulatory pathways.
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Introduction
 
Immunoregulatory CD4
 
 
 
CD25
 
 
 
 cells play a vital role in
the induction and maintenance of peripheral self-tolerance.
These professional regulatory cells prevent the activation
and proliferation of potentially autoreactive T cells that
have escaped thymic deletion or recognize extrathymic an-
tigens. Sakaguchi et al. (1) found that the transfer of
CD4
 
 
 
CD25
 
 
 
 T cells into nude mice led to the develop-
ment of organ-specific and systemic autoimmune disorders
which could be prevented by the cotransfer of CD4
 
 
 
CD25
 
 
 
 T cells. Other studies demonstrated that transfer of
CD4
 
 
 
CD25
 
 
 
 T cells prevented autoimmunity resulting
 
from neonatal thymectomy and inhibited the effector
function of autoantigen-specific T cell clones (2–4).
CD25-deficient mice develop a profound peripheral lym-
phadenopathy associated with autoimmune disorders (5).
Although these data indicate that CD4
 
 
 
CD25
 
 
 
 cells are es-
sential for self-tolerance, their role in tolerance to alloanti-
gen has not been studied.
Productive T cell activation and proliferation require
two signaling events. The first signal, antigen recognition,
is the engagement of the TCR with the MHC–peptide
ligand complex on the surface of the APCs. Costimulatory
signals are required for the full activation of the intracellular
signaling cascade, IL-2 production, T cell proliferation, and
effector function (6). In vivo blockade of the CD28/cyto-
toxic T lymphocyte–associated antigen (CTLA)-4/B7 and
CD40 ligand (CD40L)/CD40 costimulatory pathways has
been shown to induce tolerance to allografts (7–11). We
have reported previously that ex vivo blockade of the
CD40L/CD40 pathway results in tolerance induction of
murine CD4
 
 
 
 T cells to alloantigen (12, 13). Because of
the central role of CD4
 
 
 
CD25
 
 
 
 cells in self-tolerance, we
investigated the potential role of these professional suppres-
sor cells in regulating T cell responses to alloantigen and in
the induction of tolerance to alloantigen.
To determine whether CD4
 
 
 
CD25
 
 
 
 cells were required
for tolerance induction to alloantigen, we used an in vitro
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culture in which CD4
 
 
 
 T cells or CD4
 
 
 
CD25
 
 
 
 T cells
were incubated with alloantigen in the presence of anti-
CD40L or anti-B7 mAbs. Our data indicate that CD4
 
 
 
CD25
 
 
 
 T cells (8–12% of CD4
 
 
 
 cells in most strains of
mice) are essential to achieve tolerance induction by co-
stimulatory blockade as measured by antigen rechallenge in
vitro and by adoptive T cell transfer into antigen-bearing
hosts. These studies reveal a fundamental role for CD4
 
 
 
CD25
 
 
 
 cells in ex vivo tolerance induction and suggest
that CD4
 
 
 
CD25
 
 
 
 cells may be vital to tolerance induction
to alloantigen in vivo.
 
Materials and Methods
 
Mice.
 
B6.C-H2
 
bm12
 
/KhEg (bm12) mice were purchased
from The Jackson Laboratory. C57BL/6 (B6) mice were pur-
chased from the National Institutes of Health. B6 and bm12
(both H2
 
b
 
) mice differ at three amino acids due to mutations in
the class II I
 
A
 
 region.
 
In Vitro Mixed Leukocyte Reaction Cultures.
 
B6 lymph node
cells were depleted of NK cells (hybridoma PK136, rat IgG2a)
and CD8
 
 
 
 T cells (hybridoma 2.43, rat IgG2b) by incubation
with mAb, followed by passage through a goat anti–mouse and
goat anti–rat Ig-coated column (Cytovax). Purified cells were
 
 
 
94% CD4
 
 
 
 T cells. Cells, depleted of CD25
 
 
 
 cells by incuba-
tion with anti-CD25 mAb (hybridoma 3C7, rat IgG2b; BD
PharMingen) and sheep anti–rat Dynabeads (Dynal), were 99%
CD4
 
 
 
CD25
 
 
 
. Purified CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
 
 
 cells,
obtained by incubating CD4
 
 
 
 cells with anti-CD25 PE (hybrid-
oma PC61, rat IgG1; BD PharMingen) and sorting into positive
and negative fractions (
 
 
 
90 and 99% pure, respectively) (FACS
Vantage™; Becton Dickinson), were combined at the indicated
ratios. Splenic bm12 stimulators were prepared by incubation
with anti–Thy-1.2 mAb (hybridoma 30H-12, rat IgG2b) and
anti-NK1.1 mAb plus baby rabbit complement (Nieffenegger).
The phenotype of splenic stimulators was 
 
 
 
90% B cells, 1–3% T
cells, and 
 
 
 
7% macrophages. Bulk cultures of responder CD4
 
 
 
or CD4
 
 
 
CD25
 
 
 
 T cells mixed with irradiated (30 Gy) stimula-
tors at a 1:1 ratio at a final concentration of 0.5 
 
 
 
 10
 
6
 
 cells per
milliliter were plated in 24-well plates (Costar) in DMEM (Bio-
Whittaker) supplemented with 10% fetal bovine serum (Hy-
Clone), 50 mM 2-Me (Sigma Aldrich), 10 mM Hepes buffer, 1
mM sodium pyruvate (Life Technologies), amino acids (1.5 mM
 
L
 
-glutamine, 
 
L
 
-arginine, and 
 
L
 
-asparagine; Sigma Aldrich), and
antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin;
Sigma Aldrich). Anti-CD40L mAb (hybridoma MR1, hamster
IgG) or a mixture of anti-B7.1 mAb (hybridoma 16-10A1, ham-
ster IgG or 1G10, rat IgG) and anti-B7.2 mAb (hybridoma 2D10
or GL1, both rat IgG) was added to the mixed leukocyte reaction
(MLR) at 50 
 
 
 
g/ml. To determine stability of anti-CD40L mAb
in cultures, supernatants were obtained from MLR cultures after
2 and 5 d of incubation. Anti-CD40L mAb was detected at
 
 
 
80% of added concentration on both days by an anti–hamster
IgG ELISA assay (data not shown). Anti-CD40L mAb was found
to be functional as assessed by binding/blocking assays with a
CD40L-transfected cell line (data not shown). MLR cultures
were incubated at 37
 
 
 
C, 10% CO
 
2
 
. On day 9, cells were washed,
counted, and either plated with fresh stimulator cells in the ab-
sence of mAb or infused in vivo as described below. To monitor
primary and secondary MLR proliferation, responder and stimu-
lator cells were plated in replicates of six at numbers indicated in
96-well round-bottomed microtiter plates (Costar). Wells were
 
pulsed with tritiated thymidine (1 
 
 
 
Ci/well; Amersham Life Sci-
ence) on the indicated days for 20–24 h before harvesting and
counted in the absence of scintillant amplication on a 
 
 
 
-plate
reader (Packard Instrument Co.).
 
Adoptive T Cell Transfer and GVHD Lethality.
 
To determine
whether T cells tolerized to alloantigen in vitro could mount a
response to alloantigen in vivo, bm12 recipients were sublethally
irradiated with 6.0 Gy (
 
137
 
Cesium) total body irradiation 4 h be-
fore cell infusion. Control-cultured or mAb-cultured MLR cells
(10
 
5
 
) were infused into antigen-bearing bm12 recipients via tail-
vein injection. In a separate experiment, freshly purified, naive
whole CD4
 
 
 
, CD4
 
 
 
CD25
 
 
 
, whole CD4
 
 
 
 and CD4
 
 
 
CD25
 
 
 
, or
whole CD4
 
 
 
 and CD4
 
 
 
CD25
 
 
 
 cells were infused into bm12 re-
cipients. Mice were monitored daily for GVHD lethality.
 
Flow Cytometric Analysis.
 
To determine the expression of
CD40L on CD4
 
 
 
CD25
 
 
 
 versus CD4
 
 
 
CD25
 
 
 
 cells, purified cell
populations were incubated with allostimulators for 4 d in the pres-
ence of 1 
 
 
 
g/ml anti-CD40L biotin (BD PharMingen). The addi-
tion of a biotin-labeled antibody has been shown to stabilize cell
surface expression of CD40L (14). This concentration of antibody
is insufficient to inhibit alloresponses (unpublished data). Cells
Figure 1. CD4 CD25  T cells are required for tolerance induction by
CD40L/CD40 costimulatory blockade. (A) Primary MLR culture con-
sisted of 105 cells per well whole CD4  or CD4 CD25  T cell respond-
ers and 105 cells per well bm12 splenic stimulators and/or anti-CD40L
mAb. (B) Secondary MLR culture consisted of 104 cells per well re-
sponder cells from 9-d bulk cultures as described in (A) and 105 cells per
well fresh bm12 stimulators. Tritiated thymidine was added 20 h before
harvesting. On the y-axis are mean cpm   1 SEM. On the x-axis are days
in culture. One of five representative experiments is shown. 
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were incubated with anti-CD4 FITC and SA-perCP (BD Phar-
Mingen) and the level of CD40L expression evaluated on CD4
 
 
 
cells (FACScalibur™, CELLQuest™ software; Becton Dickinson).
 
Results and Discussion
 
CD4
 
 
 
CD25
 
 
 
 Cells Are Required for the Inhibition of Pri-
mary Proliferation by Anti-CD40L mAb.
 
Although data in-
dicate that CD4
 
 
 
CD25
 
 
 
 cells are essential for self-toler-
ance, their role in the induction of tolerance to alloantigen
has not been studied. We have published previously that
murine whole CD4
 
  T cells incubated with allostimulator
cells in the presence of anti-CD40L mAb results in an inhi-
bition of primary MLR, hyporesponsiveness in secondary
MLR, and tolerance to alloantigen in vivo (12, 13). To de-
termine whether CD4 CD25  cells were required for the
induction of tolerance to alloantigen via ex vivo blockade
of the CD40L/CD40 costimulatory pathway, MLR cul-
tures were established with purified whole B6 CD4  cells
or B6 CD4 CD25  cells as responders and bm12 splenic
allostimulators. As reported previously, the addition of
anti-CD40L mAb inhibited peak proliferative responses in
the whole CD4  cell population by 98% (Fig. 1 A). In
contrast, peak responses in the CD25-depleted CD4  pop-
ulation were inhibited by only 55% (Fig. 1 A). A threefold
increase in the concentration of anti-CD40L mAb did not
result in greater inhibition of primary MLR (data not
shown). Moreover, the CD25-depleted CD4  cells repro-
ducibly had a higher and more sustained peak alloresponse
than did whole CD4  control cells (5/5 experiments, Fig.
1 A, and data not shown).
Depletion of CD4 CD25  Cells Abrogated the Induction of
Hyporesponsiveness to Antigen Rechallenge In Vitro and In
Vivo. To determine whether hyporesponsiveness to antigen
rechallenge achieved in anti-CD40L mAb-treated primary
MLR cultures required CD4 CD25  cells, day-9 MLR
cultures were washed and plated with fresh bm12 splenic
stimulators in the absence of antibody. Both the whole
CD4  and the CD25-depleted CD4  control-primed cells
responded vigorously to alloantigen restimulation (Fig. 1
B). As expected, anti-CD40L–tolerized whole CD4  cells
were profoundly hyporesponsive to alloantigen restimula-
tion. In striking contrast, CD25-depleted CD4  cells that
had been cultured with anti-CD40L mAb had secondary
proliferative responses identical to (n   2 experiments) or
in excess of (n   3 experiments) the control-primed cells
Figure 2. CD4 CD25  cells regulate alloresponses both in vitro and in vivo.
(A and B) Primary MLR culture consisted of whole CD4  or CD4 CD25  T
cell responders and bm12 splenic stimulators in the absence (A) or presence (B) of
anti-CD40L mAb as in Fig.1. Purified CD4 CD25  cells were added to
CD4 CD25  cells at the percentages indicated on the x-axis. One of three rep-
resentative experiments is shown. *Significant (P   0.05) reduction as compared
with CD25  culture. (C) 105 naive whole CD4 , CD4 CD25 , whole CD4 
and CD4 CD25 , or whole CD4  and CD4 CD25  cells were adoptively
transferred into bm12 recipients. On the x-axis are days after transfer of T cells.
On the y-axis is the proportion of recipients surviving. CD4 CD25  versus any
other group, P     0.001,  n    5–8 per group;  CD4  versus CD4    
CD4 CD25 , P = 0.039; CD4  versus CD4    CD4 CD25 , P = 0.007.1314 CD4 CD25  Cells Are Required for Tolerance Induction
(Fig. 1 B, and data not shown). These data indicate that
CD4 CD25  cells were essential for the tolerization of
CD4  T cells induced via ex vivo CD40L/CD40 blockade.
To further investigate the role of CD25  cells on in vitro
alloresponses, various numbers of purified CD4 CD25 
cells were added to CD4 CD25  responder cells in both the
absence and the presence of anti-CD40L mAb and prolifera-
tion was monitored (Fig. 2). Anti-CD40L mAb inhibited
alloresponses of whole CD4  cells (containing 12%
CD4 CD25  cells) by 97% on day 4 and 99% on day 6 of
culture. In contrast, anti-CD40L mAb inhibited allore-
sponses of CD4 CD25  cells by only 25% on day 4 and
72% on day 6 as compared with whole CD4  cells (Fig. 2, A
and B). The addition of CD4 CD25  cells in the presence
of anti-CD40L mAb resulted in increasingly profound inhi-
bition of proliferation in a dose-dependent fashion (Fig. 2 B).
The addition of as few as 1% CD4 CD25  inhibited allore-
sponses of CD25  cells in the presence of anti-CD40L mAb.
Because the degree of inhibition of proliferation by CD4 
CD25  cells was more pronounced on day 6 than on day 4,
these data suggest that CD4 CD25  cells may become more
potent regulatory cells with increased culture duration. On
day 6, in the absence of antibody, the addition of 12%
CD4 CD25  cells prevented the hyperproliferative allore-
sponse of CD4 CD25  cells. The addition of 25%
CD4 CD25  cells had a pronounced suppressive effect even
in the absence of anti-CD40L mAb (Fig. 2 A). These data
indicate that CD4 CD25  cells are required for the maximal
inhibition of primary responses to alloantigen by the addition
of anti-CD40L mAb and that CD4 CD25  cells have a po-
tent capacity to regulate CD4  T cell alloresponses.
The adoptive transfer of alloreactive T cells results in
GVHD lethality, a clinically relevant in vivo model of allo-
responsiveness (12, 13). To investigate the role of
CD4 CD25  cells on alloresponses in vivo, 105 freshly iso-
lated, naive whole CD4 , CD4 CD25 , whole CD4  and
CD4 CD25 , or whole CD4  and CD4 CD25  cells
were infused into bm12 recipients (Fig. 2 C). CD4 
CD25  cells did not mediate GVHD lethality in any recip-
ients in contrast to the uniform lethality mediated by naive
whole CD4  cells 23 d after transfer. Mortality was delayed
by 8 d in mice receiving equal numbers of purified
CD4 CD25  cells and whole CD4  cells as compared
with mice receiving only whole CD4  cells (P = 0.039). In
contrast, the coinjection of CD4 CD25  cells with whole
CD4  cells accelerated GVHD mortality by 1 wk as com-
pared with recipients receiving only whole CD4  cells
(P = 0.007). These data provide further evidence that naive
CD4 CD25  T cells have a modest capacity to downregu-
late alloreactive T cells in vivo.
To determine whether CD40L was expressed on
CD4 CD25  cells, we examined cell surface expression of
Figure 3. CD4 CD25  cells upregulate CD40L on their cell surface
during incubation with allostimulators. CD4 CD25  (top) and CD4 
CD25  (bottom) cells were phenotyped for constitutive and inducible
expression of CD40L. Dotted line indicates negative control. The thin
solid line indicates the constitutive expression of freshly purified naive
cells. The bold line indicates CD40L expression after 4-d incubation
with allostimulators.
Figure 4. CD4 CD25  T cells are required for tolerance induction by
CD28/CTLA-4/B7 costimulatory blockade. (A) Primary MLR culture
consisted of whole CD4  or CD4 CD25  T cell responders and bm12
splenic stimulators and/or anti-B7 mAbs as in Fig. 1. (B) Secondary MLR
culture consisted of 104 cells per well responder cells from 9-d bulk cul-
tures as described in (A) and fresh bm12 stimulators. One of four repre-
sentative experiments is shown.1315 Taylor et al. Brief Definitive Report
CD40L on fresh, naive CD4 CD25  cells and CD4 
CD25  cells (Fig. 3). Although there was only a very mod-
est increase in constitutive expression of CD40L on CD25 
cells as compared with CD25  cells, by day 4 of culture
with allostimulators 69% of purified CD4 CD25  cells ex-
pressed CD40L. In contrast, a lower proportion (30%) of
CD4 CD25  cells expressed CD40L. These data demon-
strate that CD40L is expressed on a high proportion of
CD4 CD25  cells after alloantigen stimulation and suggest
that the CD40L/CD40 pathway may play an important
role in the regulation of alloresponses in CD4 CD25  cells.
To determine if the requirement of CD4 CD25  T
cells for tolerance induction was unique to blockade of the
CD40L/CD40 costimulatory pathway, experiments were
performed using anti-B7.1 and anti-B7.2 mAbs to block
the CD28/CTLA-4/B7 pathway. Although inhibition of
primary MLR of CD4 CD25  cells was more profound
with anti-B7 mAbs than with anti-CD40L mAb (compare
Figs. 4 A with 1 A), the degree of inhibition was not nearly
as profound as that achieved with whole CD4  cells. More
importantly, CD4 CD25  cells that had been cultured
with anti-B7 mAbs had intact or increased proliferative re-
sponses upon restimulation with alloantigen (Fig. 4 B).
These data indicate that CD4 CD25  cells are required for
the ex vivo induction of tolerance to alloantigen via co-
stimulatory blockade of either the CD40L/CD40 or the
CD28/CTLA-4/B7 pathway.
An advantage of our ex vivo tolerization model is that it
allows a clinically relevant, in vivo readout of allorespon-
siveness. To assess alloreactivity in vivo, aliquots of cells
used to establish secondary MLRs were adoptively trans-
ferred into bm12 recipients. All recipients of either whole
CD4  or CD4 CD25  control-primed cells died of
GVHD 20–25 d after transfer (Fig. 5 A). Whole CD4 
cells tolerized to alloantigen by a 9-d incubation in the
presence of anti-CD40L mAb did not mediate GVHD le-
thality providing definitive in vivo evidence that tolerance
induction had been successful. In contrast, all recipients of
anti-CD40L mAb-cultured CD4 CD25  T cells died of
GVHD 18 d after transfer (Fig. 5 A). Similar results were
seen with cultures incubated with anti-B7 mAbs (Fig. 5 B).
No recipients of anti-B7–tolerized whole CD4  cells died
of GVHD. In contrast, all recipients of anti-B7–cultured
CD25-depleted CD4  cells died of GVHD by 25 d. These
data indicate an essential requirement for CD4 CD25 
cells for tolerance induction as measured by protection
from GVHD lethality.
Collectively, our data indicate that CD4 CD25  cells
are required for the ex vivo induction of tolerance to al-
loantigen via costimulatory blockade and that CD4 
CD25  cells regulate responses to alloantigen. Previous
studies have described CD4 CD25  cells as important im-
munoregulatory cells essential for T cell homeostasis and
for the prevention of autoimmunity. Mice deficient in this
population have a high incidence of various autoimmune
disorders (1–4, 15, 16). CD4 CD25  cells have been
shown to suppress diseases induced by autoantigen-specific
T cell clones (17). Shimizu et al. (18) found that depletion
of CD4 CD25  cells resulted in the breaking of immuno-
logical tolerance to autologous tumors and evoked tumor
immunity. These studies have implicated CD4 CD25 
cells as an active mechanism for the induction and mainte-
nance of immunologic tolerance to self. Fewer studies have
addressed the role CD4 CD25  T cells may play in re-
sponse to nonself antigen. Sakaguchi et al. (1) found that
nude mice rejected allogeneic skin grafts faster if transferred
lymphocytes were first depleted of CD25  cells suggesting
that these immunoregulatory cells downregulate responses
to alloantigen. This is consistent with our finding that
CD25-depleted CD4  cells had a heightened prolifera-
tive  response to alloantigen and that the addition of
CD4 CD25  cells to either whole CD4  cells or CD25-
depleted CD4  cells had a suppressive effect on in vitro
and in vivo alloresponses. It is necessary to note that our
culture system involves direct recognition to a single MHC
class II disparity and therefore, may not be fully extrapolat-
able to other allogeneic systems. Nonetheless, our data ex-
tend the field by demonstrating an essential requirement of
Figure 5. Depletion of CD4 CD25  cells abrogated protection from
GVHD lethality induced by tolerization via costimulatory blockade. 105
cells from washed, 9-d bulk primary MLR cultures as described in Figs. 1
and 4 were injected into bm12 recipients. (A) Anti-CD40L–tolerization.
Two replicate experiments with similar results were pooled; n   16.
CD4  Anti-CD40L versus any other group, P   0.001; CD4  Primed
versus CD4 CD25  Primed, P = 0.056. (B) Anti-B7–tolerization. n   8
per group. CD4  Anti-B7 versus any other group, P   0.001.1316 CD4 CD25  Cells Are Required for Tolerance Induction
the CD4 CD25  regulatory population in allotolerance
induced by costimulatory blockade. We hypothesize that
these data implicating a professional suppressor cell popula-
tion in the regulation of immune responses to nonself anti-
gens may have important ramifications in many areas of
clinical immunology.
The mechanism for the requirement of CD4 CD25 
cells in tolerance induction remains to be elucidated. Stud-
ies are in progress to determine whether CD4 CD25  cells
are the direct targets in costimulatory blockade tolerization
strategies or if CD4 CD25  cells provide indirect but es-
sential help for tolerization of CD4 CD25  cells. Thorn-
ton and Shevach (19, 20) have shown that CD4 CD25  T
cells block the induction of IL-2 production by the
CD4 CD25  cells at the level of RNA transcription and
that activation enhances the immunosuppressive function
of these cells. Activated CD4 CD25  cells induced to be-
come potent inhibitors of IL-2 transcription could facilitate
anergy induction. Consistent with this hypothesis, IL-2
production is reduced by  90% in primary and secondary
cultures of tolerized cells (13). Moreover, the addition
of exogenous IL-2 precludes anergy induction in anti-
CD40L, mAb-treated primary culture (12). Our data indi-
cate that the activation of CD4 CD25  cells is important
in tolerance induction. The suppressive effect of the addi-
tion of 25% CD4 CD25  cells to CD4 CD25  cultures,
not evident on day 4, was profound on day 6 of culture.
Interestingly, we have found that a 4-d ex vivo incubation
with anti-CD40L mAb was insufficient to induce tolerance
in whole CD4  cells (13) suggesting a link between the ac-
tivation of CD4 CD25  cells and tolerance induction. Ta-
kahashi et al. (21) offers the intriguing suggestion that
CTLA-4 and CD28 may have unique roles in CD4 
CD25  cells with costimulation through CTLA-4 or
CD28 resulting in the activation or attenuation, respec-
tively, of suppressor function (21).
However, these findings do not address the more pro-
vocative issue of why CD4 CD25  cells are resistant to
tolerance induction via ex vivo costimulatory blockade.
One potential explanation may relate to the mechanisms by
which CD4 CD25  cells influence CD4 CD25  cells. It
has been reported recently that CTLA-4, the inhibitory T
cell receptor for B7 molecules, is constitutively expressed
on CD25 CD4  regulatory cells but not CD4 CD25 
cells (21, 22). Since CTLA-4/B7 engagement has been re-
ported to be required for the induction of peripheral T cell
tolerance in vivo (23), constitutive CTLA-4 on CD4 
CD25  cells may facilitate ex vivo tolerance induction.
CTLA-4/B7 engagement also has been shown to result in
the secretion of the immunosuppressive cytokine, TGF- ,
by CD4 CD25  cells (22) which might facilitate tolerance
induction. Although other studies have indicated that cell–
cell contact appears to be required for the downregulatory
capacity of CD4 CD25  cells, it is possible that unidenti-
fied, labile, soluble factor(s) may be involved (15, 19, 20,
24). However, we have shown that exogenously added
TGF-  alone (1 ng/ml) did not induce tolerance in our
model (25) and further, that reduced alloreactivity is not
achieved in our model via a Th2 skewing or by the pro-
duction of the immunoregulatory cytokine, IL-10 (13).
Antibodies blocking costimulation administered in vivo
can induce tolerance to donor bone marrow and organ al-
lografts (7, 26–28). It is unknown whether depletion of
host CD4 CD25  cells would preclude tolerance to donor
allografts, but it is tempting to speculate that they may also
be essential for in vivo tolerance induction to alloantigen,
at least in a strategy involving costimulatory blockade.
Future studies will address this question. Although a
CD4 CD25  T cell with suppressor function has not been
published in humans, there is evidence that professional
immune regulatory/suppressor cells with similar function,
if not phenotype, exist in humans and mice. A condition-
ing regime for allotransplant that preserves these cells may
be clinically desirable.
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